umu.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
BETA
Andersson, Jonas
Alternativa namn
Publikasjoner (10 av 16) Visa alla publikasjoner
Otten, J., Andersson, J., Ståhl, J., Stomby, A., Saleh, A., Waling, M., . . . Olsson, T. (2019). Exercise Training Adds Cardiometabolic Benefits of a Paleolithic Diet in Type 2 Diabetes Mellitus. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8(2), Article ID e010634.
Åpne denne publikasjonen i ny fane eller vindu >>Exercise Training Adds Cardiometabolic Benefits of a Paleolithic Diet in Type 2 Diabetes Mellitus
Vise andre…
2019 (engelsk)Inngår i: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, ISSN 2047-9980, E-ISSN 2047-9980, Vol. 8, nr 2, artikkel-id e010634Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: The accumulation of myocardial triglycerides and remodeling of the left ventricle are common features in type 2 diabetes mellitus and represent potential risk factors for the development of diastolic and systolic dysfunction. A few studies have investigated the separate effects of diet and exercise training on cardiac function, but none have investigated myocardial changes in response to a combined diet and exercise intervention. This 12-week randomized study assessed the effects of a Paleolithic diet, with and without additional supervised exercise training, on cardiac fat, structure, and function.

Methods and Results: Twenty-two overweight and obese subjects with type 2 diabetes mellitus were randomized to either a Paleolithic diet and standard-care exercise recommendations ( PD ) or to a Paleolithic diet plus supervised exercise training 3 hours per week ( PD - EX ). This study includes secondary end points related to cardiac structure and function, ie, myocardial triglycerides levels, cardiac morphology, and strain were measured using cardiovascular magnetic resonance, including proton spectroscopy, at baseline and after 12 weeks. Both groups showed major favorable metabolic changes. The PD - EX group showed significant decreases in myocardial triglycerides levels (-45%, P=0.038) and left ventricle mass to end-diastolic volume ratio (-13%, P=0.008) while the left ventricle end-diastolic volume and stroke volume increased significantly (+14%, P=0.004 and +17%, P=0.008, respectively). These variables were unchanged in the PD group.

Conclusions: Exercise training plus a Paleolithic diet reduced myocardial triglycerides levels and improved left ventricle remodeling in overweight/obese subjects with type 2 diabetes mellitus.

Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01513798.

sted, utgiver, år, opplag, sider
Wiley-Blackwell, 2019
Emneord
cardiovascular magnetic resonance imaging, diet, exercise, myocardial metabolism, type 2 diabetes mellitus
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-157046 (URN)10.1161/JAHA.118.010634 (DOI)000460105800010 ()30652528 (PubMedID)
Tilgjengelig fra: 2019-03-07 Laget: 2019-03-07 Sist oppdatert: 2019-03-27bibliografisk kontrollert
Lindholm, D., James, S., Andersson, J., Braun, O. O., Heller, S., Henriksson, P., . . . Varenhorst, C. (2018). Caffeine and incidence of dyspnea in patients treated with ticagrelor [Letter to the editor]. American Heart Journal, 200, 141-143
Åpne denne publikasjonen i ny fane eller vindu >>Caffeine and incidence of dyspnea in patients treated with ticagrelor
Vise andre…
2018 (engelsk)Inngår i: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 200, s. 141-143Artikkel i tidsskrift, Letter (Fagfellevurdert) Published
sted, utgiver, år, opplag, sider
Elsevier, 2018
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-150880 (URN)10.1016/j.ahj.2018.02.011 (DOI)000434948300021 ()29898843 (PubMedID)2-s2.0-85043362910 (Scopus ID)
Tilgjengelig fra: 2018-08-31 Laget: 2018-08-31 Sist oppdatert: 2019-05-24bibliografisk kontrollert
Völz, S., Spaak, J., Elf, J., Jägrén, C., Lundin, C., Stenborg, A., . . . Andersson, B. (2018). Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation. Journal of Hypertension, 36(1), 151-158
Åpne denne publikasjonen i ny fane eller vindu >>Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation
Vise andre…
2018 (engelsk)Inngår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 36, nr 1, s. 151-158Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Renal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry. Purpose: To assess the safety and efficacy of RDN on patients with resistant hypertension in a real-world clinical setting. Methods: This nationwide database contains patient characteristics, procedural details, and follow-up data on all RDN procedures performed in Sweden. Consecutive procedures between 2011 and 2015 were included. Results: The data analysis consists of 252 patients (mean age 61 +/- 10 years, 38% women; mean 4.5 +/- 1.5 antihypertensive drugs). Office SBP and DBP and 24-h ambulatory blood pressure (BP) decreased 6 months after RDN (176 +/- 23/97 +/- 17 to 161 +/- 26/91 +/- 16 mmHg, both P<0.001; and 155 +/- 17/89 +/- 14 to 147 +/- 18/82 +/- 12 mmHg, both P<0.001). Significant office and ambulatory BP reductions persisted throughout the observation period of 36 months. Major procedure-related vascular complications occurred in four patients. Renal function and number of antihypertensive drugs were unchanged during follow-up. Conclusion: In this complete national cohort, RDN was associated with a sustained reduction in office and ambulatory BP in patients with resistant hypertension. The procedure proved to be feasible and associated with a low-complication rate, including long-term adverse events.

sted, utgiver, år, opplag, sider
Lippincott Williams & Wilkins, 2018
Emneord
ambulatory blood pressure, office blood pressure, registry, renal denervation, resistant hypertension
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-154728 (URN)10.1097/HJH.0000000000001517 (DOI)000429316200021 ()29210862 (PubMedID)
Tilgjengelig fra: 2018-12-28 Laget: 2018-12-28 Sist oppdatert: 2018-12-28bibliografisk kontrollert
Erlinge, D., Omerovic, E., Frobert, O., Linder, R., Danielewicz, M., Hamid, M., . . . James, S. (2017). Bivalirudin versus heparin monotherapy in myocardial infarction. New England Journal of Medicine, 377(12), 1132-1142
Åpne denne publikasjonen i ny fane eller vindu >>Bivalirudin versus heparin monotherapy in myocardial infarction
Vise andre…
2017 (engelsk)Inngår i: New England Journal of Medicine, ISSN 0028-4793, E-ISSN 1533-4406, Vol. 377, nr 12, s. 1132-1142Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y 12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors.

METHODS In this multicenter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y(12) inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end point was a composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-up.

RESULTS A total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial. At 180 days, a primary end-point event had occurred in 12.3% of the patients (369 of 3004) in the bivalirudin group and in 12.8% (383 of 3002) in the heparin group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.10; P = 0.54). The results were consistent between patients with STEMI and those with NSTEMI and across other major subgroups. Myocardial infarction occurred in 2.0% of the patients in the bivalirudin group and in 2.4% in the heparin group (hazard ratio, 0.84; 95% CI, 0.60 to 1.19; P = 0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ratio, 1.00; 95% CI, 0.84 to 1.19; P = 0.98), definite stent thrombosis in 0.4% and 0.7%, respectively (hazard ratio, 0.54; 95% CI, 0.27 to 1.10; P = 0.09), and death in 2.9% and 2.8%, respectively (hazard ratio, 1.05; 95% CI, 0.78 to 1.41; P = 0.76).

CONCLUSIONS Among patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy. (Funded by the Swedish Heart-Lung Foundation and others; VALIDATE-SWEDEHEART Clinical-TrialsRegister.eu number, 2012-005260-10; ClinicalTrials.gov number, NCT02311231.)

sted, utgiver, år, opplag, sider
Massachusetts Medical Society, 2017
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-140649 (URN)10.1056/NEJMoa1706443 (DOI)000411348500007 ()28844201 (PubMedID)
Tilgjengelig fra: 2017-10-17 Laget: 2017-10-17 Sist oppdatert: 2019-05-17bibliografisk kontrollert
Andersson, J., Mellberg, C., Otten, J., Ryberg, M., Rinnström, D., Larsson, C., . . . Olsson, T. (2016). Left ventricular remodelling changes without concomitant loss of myocardial fat after long-term dietary intervention. International Journal of Cardiology, 216, 92-96
Åpne denne publikasjonen i ny fane eller vindu >>Left ventricular remodelling changes without concomitant loss of myocardial fat after long-term dietary intervention
Vise andre…
2016 (engelsk)Inngår i: International Journal of Cardiology, ISSN 0167-5273, E-ISSN 1874-1754, Vol. 216, s. 92-96Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Accumulation of myocardial triglycerides (MTG) is associated with impaired left ventricular (LV) remodelling and function in obese and diabetic subjects. The role of MTG accumulation in development of heart failure in this group of patients is unknown. Short-term studies suggest that diets that lead to weight loss could mobilize MTG, with a favourable effect on cardiac remodelling. In a 24-month, randomized, investigator-blinded study, we assessed the effect of two different diets and subsequent weight loss on cardiac function and MTG in postmenopausal women. Methods: Sixty-eight healthy postmenopausal women with body mass index [BMI] >= 27 kg/m(2) were randomized to an ad libitum Palaeolithic diet (PD) or a Nordic Nutrition Recommendation (NNR) diet for 24 months. Morphology, cardiac function, and MTG levels were measured using magnetic resonance (MR) scanning, including proton spectroscopy at baseline and 6 and 24 months. Results: Despite mean weight losses of 4.9 (1.0) kg (NNR) and 7.8 (1.1) kg (PD), the MTG content did not change over time (p = 0.98 in the NNR and p = 0.11 in the PD group at 24 months). Reduced left ventricular mass was observed in both diet groups over 24 months. Blood pressure was reduced at 6 months, but returned to baseline levels at 24 months. End diastolic volume, stroke volume, and cardiac output decreased over time. No differences between diet groups were observed. Conclusions: Diet intervention and moderate weight loss over 24 months improved LV remodelling but did not alter MTG levels in overweight/obese postmenopausal women.

Emneord
Cardiac Magnetic Resonance (CMR) imaging, Diet, Metabolic heart disease, Obesity, Weight reduction
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-123040 (URN)10.1016/j.ijcard.2016.04.050 (DOI)000376820700015 ()27149238 (PubMedID)
Tilgjengelig fra: 2016-08-26 Laget: 2016-06-27 Sist oppdatert: 2018-06-07bibliografisk kontrollert
Lagerqvist, B., Fröbert, O., Olivecrona, G. K., Gudnason, T., Maeng, M., Alström, P., . . . James, S. K. (2014). Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction. New England Journal of Medicine, 371(12), 1111-1120
Åpne denne publikasjonen i ny fane eller vindu >>Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction
Vise andre…
2014 (engelsk)Inngår i: New England Journal of Medicine, ISSN 0028-4793, E-ISSN 1533-4406, Vol. 371, nr 12, s. 1111-1120Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND Routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortality. We evaluated clinical outcomes at 1 year after thrombus aspiration. METHODS We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by PCI or to undergo PCI alone, in a registry-based, randomized clinical trial. The primary end point of all-cause mortality at 30 days has been reported previously. Death from any cause at 1 year was a prespecified secondary end point of the trial. RESULTS No patients were lost to follow-up. Death from any cause occurred in 5.3% of the patients (191 of 3621 patients) in the thrombus-aspiration group, as compared with 5.6% (202 of 3623) in the PCI-only group (hazard ratio, 0.94; 95% confidence interval [CI], 0.78 to 1.15; P = 0.57). Rehospitalization for myocardial infarction at 1 year occurred in 2.7% and 2.7% of the patients, respectively (hazard ratio, 0.97; 95% CI, 0.73 to 1.28; P = 0.81), and stent thrombosis in 0.7% and 0.9%, respectively (hazard ratio, 0.84; 95% CI, 0.50 to 1.40; P = 0.51). The composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis occurred in 8.0% and 8.5% of the patients, respectively (hazard ratio, 0.94; 95% CI, 0.80 to 1.11; P = 0.48). The results were consistent across all the major subgroups, including grade of thrombus burden and coronary flow before PCI. CONCLUSIONS Routine thrombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or the composite of death from any cause, rehospitalization for myocardial infarction, or stent thrombosis at 1 year.

sted, utgiver, år, opplag, sider
Massachusetts Medical Society, 2014
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-94539 (URN)10.1056/NEJMoa1405707 (DOI)000341687300006 ()25176395 (PubMedID)
Tilgjengelig fra: 2014-11-13 Laget: 2014-10-13 Sist oppdatert: 2018-12-27bibliografisk kontrollert
Rydén, M., Agustsson, T., Andersson, J., Bolinder, J., Toft, E. & Arner, P. (2012). Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states. Journal of Internal Medicine, 271(4), 414-420
Åpne denne publikasjonen i ny fane eller vindu >>Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states
Vise andre…
2012 (engelsk)Inngår i: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 271, nr 4, s. 414-420Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective Zinc-α2-glycoprotein (ZAG) has been proposed as a tumour-derived cancer cachexia factor. However, ZAG is produced by some normal tissues, including white adipose tissue (WAT), and high serum ZAG levels are present in nonmalignant conditions. We determined whether human WAT contributes to serum ZAG levels and how serum and WAT-secreted ZAG levels correlate with catabolism in patients with cancer and in obese subjects undergoing a very low-calorie diet (VLCD) for 11 days.

Design/subjects ZAG levels in serum and in conditioned medium from WAT/adipocytes were determined by enzyme-linked immunosorbent assay. ZAG release from WAT in vivo was determined in 10 healthy subjects. The correlation between ZAG and cachexia was studied in 34 patients with newly diagnosed gastrointestinal cancer. The impact of a VLCD on ZAG release and serum levels was assessed in 10 obese women.

Results ZAG was released from abdominal WAT and adipocytes in vitro. However, the arteriovenous differences in vivo showed that there was no significant contribution of WAT to the circulating levels. WAT-secreted but not serum ZAG correlated positively with poor nutritional status but not with fat mass (or body mass index) in patients with gastrointestinal cancer. In obese subjects on a VLCD, ZAG secretion from WAT increased significantly whereas serum levels remained unaltered.

Conclusions ZAG is released from human WAT, but this tissue does not contribute significantly to the circulating levels. WAT-secreted ZAG correlates with nutritional status but not with fat mass in both cancer and nonmalignant conditions. Adipose ZAG is therefore a local factor activated primarily by the catabolic state per se.

sted, utgiver, år, opplag, sider
Wiley-Blackwell, 2012
Emneord
adipocyte, cachexia, cancer, nutrition, obesity, secretion
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-51163 (URN)10.1111/j.1365-2796.2011.02441.x (DOI)000301927100011 ()21883534 (PubMedID)
Tilgjengelig fra: 2012-01-11 Laget: 2012-01-11 Sist oppdatert: 2018-12-27bibliografisk kontrollert
Andersson, J., Karpe, F., Sjöström, L.-G., Riklund, K., Söderberg, S. & Olsson, T. (2012). Association of adipose tissue blood flow with fat depot sizes and adipokines in women. International Journal of Obesity, 36(6), 783-789
Åpne denne publikasjonen i ny fane eller vindu >>Association of adipose tissue blood flow with fat depot sizes and adipokines in women
Vise andre…
2012 (engelsk)Inngår i: International Journal of Obesity, ISSN 0307-0565, E-ISSN 1476-5497, Vol. 36, nr 6, s. 783-789Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: To explore possible associations between adipose tissue (AT) blood flow (ATBF), AT depot sizes and adipocyte-derived hormones (adipokines) in women.

Subjects: In all, 43 healthy women were divided into four groups: normal-weight (n=11) and obese (n=11) pre-menopausal women and normal-weight (n=10) and obese (n=11) post-menopausal women.

Methods: Fasting levels of adipokines were obtained, and a single-slice computed tomography scan at the level of L4-L5 was used to estimate fat depot sizes. ATBF was assessed by xenon washout while in a fasting state and after oral glucose load. We also measured glucose, insulin and non-esterified fatty acids.

Results: Total, subcutaneous and visceral AT areas strongly correlated with ATBF (all P<0.001). Circulating leptin levels strongly and inversely correlated with ATBF (P=0.001), but this association did not remain after adjustment for body mass index. Adiponectin was not associated with blood flow.

Conclusion: ATBF is closely linked to subcutaneous and visceral AT size. Further analyses are needed to determine possible mediators of this association, including mechanistic studies to assess a putative role for leptin as a significant modulator of blood flow. International Journal of Obesity advance online publication, 26 July 2011; doi:10.1038/ijo.2011.152.

sted, utgiver, år, opplag, sider
Nature Publishing Group, 2012
Emneord
adipose tissue, blood flow, body fat distribution, leptin, women
HSV kategori
Forskningsprogram
medicin
Identifikatorer
urn:nbn:se:umu:diva-48345 (URN)10.1038/ijo.2011.152 (DOI)000305282400004 ()21792171 (PubMedID)
Tilgjengelig fra: 2011-10-19 Laget: 2011-10-18 Sist oppdatert: 2018-12-27bibliografisk kontrollert
Andersson, J. (2011). Adipose tissue as an active organ:  blood flow regulation and tissue-specific glucocorticoid metabolism. (Doctoral dissertation). Umeå: Umeå universitet
Åpne denne publikasjonen i ny fane eller vindu >>Adipose tissue as an active organ:  blood flow regulation and tissue-specific glucocorticoid metabolism
2011 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Background: Despite advances in the treatment of atherosclerosis, cardiovascular disease is the leading cause of death worldwide. With the population getting older and more obese, the burden of cardiovascular disease may further increase. Premenopausal women are relatively protected against cardiovascular disease compared to men, but the reasons for this sex difference are partly unknown. Redistribution of body fat from peripheral to central depots may be a contributing factor. Central fat is associated with hyperlipidemia, hyperglycemia, hypertension, and insulin resistance. Two possible mediators of these metabolic disturbances are tissue-specific production of the stress hormone cortisol and adipose tissue blood flow (ATBF). The aim of this thesis was to determine the adipose tissue production of cortisol by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and to investigate the regulation of ATBF.

Materials and Methods: Cortisol release was estimated by labeled cortisol infusions and tissue-specific catheterizations of subcutaneous and visceral adipose tissue (VAT) in men. We investigated ATBF by 133Xe-washout and its relation to autonomic activity, endothelial function, adipose tissue distribution, and adipokines in different groups of women. We further investigated the effect of two diets and of weight loss on ATBF in women.

Results: We demonstrated significant cortisol release from subcutaneous adipose tissue in humans. Splanchnic cortisol release was accounted for entirely by the liver. Cortisol release from VAT (to the portal vein) was not detected. ATBF decreased according to increasing weight and postmenopausal status, and the level of blood flow was associated with nitric oxide (NO) activity and autonomic activity. ATBF was also highly associated with leptin levels and both subcutaneous adipose tissue and VAT areas. After 6 months of diet and weight reduction, a significant difference in ATBF was observed between diet groups.

Conclusions: Our data for the first time demonstrate the contributions of cortisol generated from subcutaneous adipose tissue, visceral tissues, and liver by 11β-HSD1. ATBF is linked to autonomic activity, NO activity, and the amount of adipose tissue (independent of fat depot). Postmenopausal overweight women exhibited a loss of ATBF flexibility, which may contribute to the metabolic dysfunction seen in this group. Weight loss in a diet program could not increase the ATBF, although there were ATBF differences between diet groups. The results will increase understanding of adipose tissue biology and contribute to the development of treatment strategies targeting obesity and obesity-related disorders.

sted, utgiver, år, opplag, sider
Umeå: Umeå universitet, 2011. s. 87
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1444
Emneord
11β-hydroxysteroid dehydrogenase type 1, adipose tissue, autonomic nervous system, blood flow, cortisol, nitric oxide, weight loss.
HSV kategori
Forskningsprogram
medicin
Identifikatorer
urn:nbn:se:umu:diva-48415 (URN)978-91-7459-280-1 (ISBN)
Disputas
2011-11-11, Hörsal Betula, byggnad 6M, Norrlands Universitetssjukhus, Umeå, 09:00 (svensk)
Opponent
Veileder
Forskningsfinansiär
Swedish Research Council
Tilgjengelig fra: 2011-10-21 Laget: 2011-10-19 Sist oppdatert: 2018-06-08bibliografisk kontrollert
Lång, P., Zakaroff-Girard, A., Wåhlén, K., Andersson, J., Olsson, T., Bambace, C., . . . Arner, P. (2011). Expression and secretion of the novel adipokine tartrate-resistant acid phosphatase from adipose tissues of obese and lean women. International Journal of Obesity, 35(12), 1502-1510
Åpne denne publikasjonen i ny fane eller vindu >>Expression and secretion of the novel adipokine tartrate-resistant acid phosphatase from adipose tissues of obese and lean women
Vise andre…
2011 (engelsk)Inngår i: International Journal of Obesity, ISSN 0307-0565, E-ISSN 1476-5497, Vol. 35, nr 12, s. 1502-1510Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: Tartrate-resistant acid phosphatase (TRAP) expressed by adipose tissue macrophages (ATMs) induces mice obesity and human adipocyte differentiation in vitro. This study aimed to investigate whether TRAP was secreted differently from human obese versus lean adipose tissues and to identify the cellular source of adipose tissue TRAP.

Design: Subcutaneous adipose tissues obtained from healthy subjects. Enzyme-linked immunosorbent assays (ELISAs) for total (5a+5b) and cleaved TRAP (5b) were used. TRAP secretion was determined in adipose tissue biopsies, and mRNA expression was studied in cell types isolated from the same.

Subjects: Results of 24 lean and 24 obese women (in vitro) and 8 subjects (in vivo) were compared. The main outcome measurements were TRAP expression and secretion in vitro and in vivo.

Results: In-house total TRAP ELISA showed high sensitivity and a coefficient of variance of 11%. Adipose secretion of total TRAP was linear in vitro with time and was evident in vivo. Total TRAP secretion in vitro was similar in lean and obese women expressed per unit weight of the adipose tissue but correlated positively with the number/size of adipocytes (P≤0.01) and with adipose secretion of tumor necrosis factor-α and interleukin-6 (P<0.01). TRAP 5b was not secreted from the adipose tissue. ATMs displayed highest cellular expression of TRAP mRNA in adipose tissue cells derived from lean or obese women.

Conclusions: TRAP is a novel human adipokine produced by macrophages and secreted from the subcutaneous adipose tissue in vivo and in vitro. Secretion is linked to the size and number of adipocytes, as well as to concomitant secretion of inflammatory mediators, suggesting that TRAP is involved in fat accumulation and adipose inflammation. International Journal of Obesity advance online publication, 8 March 2011; doi:10.1038/ijo.2011.17.

Emneord
tartrate-resistant acid phosphatase, acid phosphatase type 5, macrophages, adipose tissue, adipokine, inflammation
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-45876 (URN)10.1038/ijo.2011.17 (DOI)000298414500007 ()21386798 (PubMedID)
Tilgjengelig fra: 2011-08-19 Laget: 2011-08-19 Sist oppdatert: 2018-12-27bibliografisk kontrollert
Organisasjoner